Curated News
By: NewsRamp Editorial Staff
September 30, 2026
Onco-Innovations Advances ONC010 with $5M Financing and Key Milestones
TLDR
- Onco-Innovations advances ONC010 with CAD$5M financing and 99.3% purity API scale-up, gaining an edge in oncology drug development.
- Onco-Innovations ONC010, a nanoparticle-encapsulated PNKP inhibitor, disrupts DNA repair, with completed 300-gram API scale-up and IND-enabling activities.
- Onco-Innovations pursues cancer treatments that could improve survival and overcome resistance, making tomorrow better for patients worldwide.
- Onco-Innovations uses nanoparticles to inhibit PNKP, potentially breaking cancer resistance, and has secured CAD$5M for development.
Impact - Why it Matters
This news matters because Onco-Innovations is making significant strides in developing a novel cancer therapy that could overcome treatment resistance, a major challenge in oncology. The successful scale-up of ONC010 with high purity and the secured financing provide a clear path toward clinical trials, potentially offering new hope for patients with solid tumors. Moreover, the involvement of NetworkNewsWire and IBN underscores the importance of effective communication and investor awareness in bringing innovative biotech solutions to market.
Summary
Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its preclinical oncology candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms involved in cancer survival and treatment resistance. The company has completed a 300-gram API scale-up with approximately 99.3% purity, expanded manufacturing capabilities through a partnership with Nanosoft Polymers, and is progressing metabolism, analytical, licensing, and other IND-enabling activities. To support these efforts, Onco-Innovations has arranged approximately CAD$5 million in institutional financing, to be released through 18 monthly tranches, which will fund ONC010 development, the SynoGraph platform, and general corporate needs. The appointment of Dave Antony as CFO adds financial and corporate experience as the company continues IND-enabling work toward a planned Phase 1 study of ONC010 in Australia.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. For more information, visit the company’s website at https://oncoinnovations.com/. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://nnw.fm/ONNVF.
The announcement was disseminated by NetworkNewsWire (“NNW”), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Onco-Innovations Advances ONC010 with $5M Financing and Key Milestones
